Abstract
Objectives: Aim is to study of the therapeutic efficacy of atypical antipsychotics (aripiprazole and quetiapine) in comparison with haloperidol in cases of comorbidity of low-grade forms of schizophrenia and addiction. Material and methods: A randomized comparative study of these antipsychotic preparations was conducted during the period Feb-May 2021. We screened 90 men admitted to treatment in a narcological hospital. Of these, 54 (60%) patients those had a previously established diagnosis of schizophrenia, 36 (40%) did not. Patients by simple randomization were divided into three groups of 30 people each, in which the appropriate antipsychotic was prescribed: aripiprazole in dose up to 20 mg / day, quetiapine at a dose of up to 600 mg / day, haloperidol at a dose of up to 30 mg / day. Results: Intra-group analysis of the dependent variables on the ANSS, BPRS, VAS, PVN scales showed an appropriate significant difference in all groups in the dynamics of therapy. Intergroup analysis of independent variables showed significant correct differences between aripiprazole and haloperidol according to PANSS, BPRS to visit 4, according to VAS to visit 3, according to the PVI scale to visit 2. Intergroup analysis of independent variables showed significant differences between quetiapine and haloperidol by PANSS, VAS, and PVI scale -by visit 4. Conclusion: Based on the results of the correlation analysis, waters about the inextricable connection between psychopathological manifestations of schizophrenia and the syndrome of pathological attraction to psychoactive substances.